Buy & Sell iShares International Treasury Bond ETF (IGOV) – iShares International Treasury Bond ETF Price Today
Key Stats
- -Market Cap
- -Sector
- -5.7%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 73 daysTypical Hold Time
Over the past 52 weeks, iShares International Treasury Bond ETF has traded between a low of $40.54 and a high of $43.19, highlighting its annual price range. Over the past three months, iShares International Treasury Bond ETF has recorded a drawdown of -5.7%, reflecting recent price volatility. On average, investors hold iShares International Treasury Bond ETF for approximately 73 days, indicating typical investor behavior on the platform.
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Most Recent News
Boston Scientific invests $1.5B for stake in MiRus, targeting advanced aortic stenosis treatment.
Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a n...
Elliott sees hidden value in Bio-Rad via $5B Sartorius stake amid share price slump
Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories, which develops medical instruments and software. Bio-Rad's founding family retains majority voting control, complicating activist efforts. Elliott ...
Regeneron's melanoma trial fails, stock drops over 10%, investors urged to explore legal options.
Regeneron Pharmaceuticals announced that its Phase 3 melanoma trial combining fianlimab and Libtayo did not meet the primary endpoint against Keytruda, causing the stock to fall more than 10%. Prior optimism from company executives about the trial's ...
